Novartis' Certican To Get Advisory Committee Review For Heart Transplant Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
The proliferation inhibitor everolimus will be reviewed by FDA's Cardiovascular & Renal Drugs Advisory Committee on Nov. 16.